FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Kirchgraber Paul R	2. Date of Event Requiring Statement (Month/Day/Year) 11/01/2019  3. Issuer Name and Ticker or Trading Symbol LABORATORY CORP OF AMERICA HOLDINGS [ LH ]						[LH]			
(Last) (First) (Middle) 531 SOUTH SPRING STREET	11/01/2013		4. Relationship of Reporting Perso (Check all applicable) Director	on(s) to Issuer 10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)				
			X Officer (give title below)	Other (spe below)		i. Individual or Joint Applicable Line)	d/Group Filing (Check			
(Street) BURLINGTON NC 27215			CEO, Covance Drug D	Development		X Form filed by One Reporting Person				
BURLINGTON INC 2/215						Form filed by More than One Reporting Person				
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			Amount of Securities eneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  4. Nature of Indirect Beneficial Ownership (Instr. 5)		Beneficial Ownership				
Common Stock			4,407	D						
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Security	rity (Instr. 4) Conve or Exe		ise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivativ Security	e Direct (D) or Indirect (I) (Instr. 5)				
Restricted Stock Unit	(1)	(1)	Common Stock	527	(2)	D				
Restricted Stock Unit	(3)	(3)	Common Stock	950	(2)	D				
Restricted Stock Unit	(4)	(4)	Common Stock	337	(2)	D				
Restricted Stock Unit	(5)	(5)	Common Stock	2,020	(2)	D				

## Explanation of Responses:

- $1.\ The\ Restricted\ Stock\ Units\ vest\ in\ three\ equal\ annual\ installments\ beginning\ on\ 2/12/2019.$
- 2. Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- $3.\ The\ Restricted\ Stock\ Units\ vest\ in\ three\ equal\ annual\ installments\ beginning\ on\ 2/12/2020.$
- $4. \ The \ Restricted \ Stock \ Units \ vest \ in \ three \ equal \ annual \ installments \ beginning \ on \ 2/7/2018.$
- 5. The Restricted Stock Units vest in three equal annual installments beginning on 4/3/2019.

/s/ Sandra van der Vaart,

Attorney-in-Fact for Paul R. 11/01/2019

Kirchgraber

\*\* Signature of Reporting Person Date

 $\label{lem:Reminder:Report on a separate line for each class of securities beneficially owned directly or indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 $Note: File \ three \ copies \ of \ this \ Form, \ one \ of \ which \ must \ be \ manually \ signed. \ If \ space \ is \ insufficient, \ see \ Instruction \ 6 \ for \ procedure.$ 

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra D. van der Vaart attorney-in-fact and agent, in connection with the filing for the undersigned on Form 3, Form 4, and Form 5 under the Securities Act of 1934, as amended, including, without limiting the generality of the foregoing, to sign the Form 3, Form 4, and Form 5 with respect to the undersigned's holding of and transactions in securities issued by Laboratory Corporation of America Holdings, in the name and on behalf of the undersigned as an officer of Laboratory Corporation of America Holdings, and any amendments to the Form 3, Form 4, or Form 5 and any instrument, contract, document or other writing, of or in connection with the Form 3, Form 4, and Form 5 or amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorney-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents, each acting alone, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall become effective immediately, and shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5, with respect to the undersigned's holdings of and transactions in securities issued by Laboratory Corporation of America Holdings, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has signed these presents this 27th day of September, 2019.

/s/ Paul Kirchgraber
-----Paul Kirchgraber